Grant Award Details
Grant Application Details
- Phase 2 Study of Hematopoietic Stem Cell Gene Transfer Inducing Fetal Hemoglobin in Sickle Cell Disease
Therapeutic Candidate or Device
Autologous CD34+ cells transduced ex vivo with the BCH_BB694 LCR(-HS4) bGp D12shmiR lentiviral vector
Sickle cell disease with severe phenotype.
Silencing of beta-sickle globin and induction of anti-sickling fetal hemoglobin
Unmet Medical Need
Sickle cell is a severe disease with protean manifestations. The only curative therapy is an allogeneic stem cell transplant, optimally with an HLA-identical sibling donor. However, <20% of sickle cell patients have such a donor available.
Completion of pilot and instigation of phase 2
Major Proposed Activities
- Enrollment of one patient to fill remaining slot of pilot study and enrollment of patients on continuing phase 2 study.
- Development and validation of cell manufacturing in CA site to support west coast enrollment, including CA sites.
- Clinical and cell manufacturing site monitoring of CA sites.
Sickle cell disease (SCD) is a genetic condition mainly affecting African-Americans and those of certain Hispanic ethnic background. SCD has major morbidity with significant ongoing medical care costs. We are seeking a permanent therapy that mitigates the major morbidities. If successful, this treatment would significantly enhance the lives of affected individuals and reduce the lifelong financial burden of medical care, lost productivity and underemployment for individuals with severe SCD.